Inhibrx to Present Clinical Data at Upcoming Global Medical Conferences

The schedule begins October 25 at the European Society for Medical Oncology Congress in Madrid, where Jong Chul Park will deliver an oral presentation on the phase 2 primary analysis of ordastobart. The study evaluates the hexavalent OX40 agonist in combination with pembrolizumab as a first-line treatment for patients with PD-L1–high recurrent or metastatic head and neck squamous cell carcinoma.

In late October, the focus shifts to Miami for the Musculoskeletal Tumor Society Annual Meeting. Robin Jones will present secondary efficacy endpoints from the randomized, registrational phase 2 ChonDRAgon study regarding ozekibart’s application in conventional chondrosarcoma. The research continues in November at the Connective Tissue Oncology Society meeting in Seoul. There, Sant Chawla will provide updated progression-free survival data from the ChonDRAgon study, while Varun Monga will present a poster detailing a phase 1/2 study of ozekibart combined with irinotecan and temozolomide for adolescents and adults suffering from Ewing sarcoma. Interested parties can access the materials on the company's investor portal as the events commence.